Until the 1970s, the study of amine mediators such as noradrenaline, histamine and acetylcholine dominated pharmacological research. The discovery of the prostaglandins heralded a decade of research in which lipid mediators took pride of place. But since 1987 the research community has had to contend with yet another class of biological mediators-gases.
Until the 1970s, the study of amine mediators such as noradrenaline, histamine and acetylcholine dominated pharmacological research. The discovery of the prostaglandins heralded a decade of research in which lipid mediators took pride of place. But since 1987 the research community has had to contend with yet another class of biological mediators-gases.
Nitric oxide is the first endogenously synthesized gas shown to have a physiological mediator function and in the past 8 years over 15 000 papers have been published on the molecular biology, biochemistry, pharmacology and clinical significance of this most unexpected of mediators. This review is based on a meeting at which some of the major contributors to this area of research distilled the welter of data to present an update and overview of the biology of NO in the cardiovascular, immune and nervous systems. The main speakers are listed at the end.
DISCOVERY OF NO
The discovery of NO is a story of serendipity, a sharp eye and imaginative, adventurous research. Amines and gases came together in the New York laboratory of Robert Furchgott, SUNY Health Center, BrooklynI. He was investigating mechanisms of contraction and relaxation of isolated blood vessels when he noticed that one of his technicians always found that acetylcholine relaxed the vessels whereas the other found that it caused contraction. The answer to this paradox lay in the fragile monolayer of endothelial cells that lines the luminal surface of blood vessels. One technician (like countless investigators before) handled the vessel roughly and inadvertently rubbed off the endothelium. The other was careful and (equally inadvertently) kept the endothelium intact. Furchgott understood what he saw and went on to demonstrate that the presence of an intact endothelium is a prerequisite for the relaxant effects of acetylcholine, bradykinin, substance P and various other mediators. By separating the endothelium from the smooth muscle he showed that a labile factor is released from the endothelium and it is this factor that relaxes the smooth muscle.
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Institute, University College London, London WC1E 6JJ, England Correspondence: Professor Patrick Vallance NITRIC OXIDE'AND ITSCLINICAL IMPLICATIONS, RSM CONFERENCE, 11 JUNE 1996 6 years after his discovery of endothelium-derived relaxing factor (EDRF), Furchgott surprised vascular pharmacologists again. He suggested that EDRF was an inorganic gas, nitric oxide-a substance hitherto thought of as a pollutant, a product of electrochemical storms, a toxic contaminant of cylinders of nitrous oxide. But within a year, Moncada and co-workers/ demonstrated that vascular endothelial cells generate NO, showed that the amounts generated account for the biological activity of EDRF, identified the substrate for NO synthesis (L-arginine), and synthesized an inhibitor of NO formation (L-NMMA) ( Figure 1 ). Drawing on the technology developed by scientists studying pollution, they adapted a chemiluminescence machine built for detecting NO released in car exhaust, increased the sensitivity, and attached it to columns of endothelial cells grown onto miniaturized glass beads. Upon stimulation of the endothelial cells NO was detected and the amount was sufficient to relax vascular smooth muscle.
HOW DOES NO ACT?
Before the chemical identity of EDRF was known, it was recognized that endothelium-dependent relaxation of blood vessels was associated with an increase in the levels of cyclic GMP in the vascular smooth muscle.', cGMP is produced upon activation of guanylate cyclase, a magnesium-sensitive 
SYNTHESIS OF NO
It is now clear that the endothelium -dcpcndent relaxation 
NO, IMMUNITY AND INFLAMMATION
At a time when vascular pharmacologists were pursuing the identity of EDRF, immunologists were independently exploring the cytotoxic properties of macrophages that appeared to be dependent on generation of an oxide of nitrogen". It is now clear that activated macrophages express high levels of NOS and produce large amounts of NO. Cytokines that induce the expression of iNOS in macrophages include interleukin-l (IL-I), interferon-y (IFN-y), tumour necrosis factor-a (TNF-CX) and migration inhibitory factor. The NO generated contributes to the role of macrophages as highly effective killers of intracellular and extracellular pathogens-although NO itself is probably not the cytotoxic molecule; rather it may be peroxynitrite (ONOO-') a product of the interaction between NO and superoxidc (0 2 -).
It is also apparent that excessive NO can contribute to experimental immunopathology (diabetes, graft-versus-host disease, liver cirrhosis, rheumatoid arthritis) and expression of iNOS is thus necessarily under tight regulation. Several cytokines, including IL-4, IL-10 9 , 1O and transforming growth factor-beta, can down-regulate the induction of NO synthase in macrophages. In addition, macrophages exposed to endotoxin alone and then stimulated with a mix of IFN-y and endotoxin express lower levels of NO synthase than cells stimulated without pre-exposure to endotoxin (i.e, they exhibit tolerance). NO itself can reduce the activity of NO synthase by feedback inhibition, and also inhibit the production of IFN-y by Th l cells (thus turning off its own synthesis from upstream in the inflammation cascade). iNOS expression is involved not only in macrophage biology, but also in the response of a wide variety of cells to inflammation and infection (see below).
NO IN THE CARDIOVASCULAR SYSTEM
All three isoforms of NOS have been implicated in cardiovascular control. There is a basal generation of NO in the arterial circulation of animals and human beings and this provides a continuous vasodilatortone (eNOS activity). Indeed, inhibition of NO synthesis causes substantial arteriolar vasoconstriction and incTeased blood pressure; genetically modified mice that lack the gene encoding for eNOS (eNOS knockout mice) are hypertensive l ! . The tonic NO-mediated dilatation of resistance vessels seems to be approximately equal in magnitude and opposite in effect to the tonic constriction produced by the sympathetic nervous system, suggesting that these two systems might work together to allow vascular tone to be adjusted rapidly in response to a variety of central and local stimuli; the sympathetic nervous system providing a mechanism for central control and endothelium-derived NO a system for local control.
The endothelium responds to chemical stimulation (e.g. agonists such as acetylcholine or bradykinin) and physical stimulation (e.g. shear stress). The precise mechanisms by which these different stimuli increase intracellular eNOS activity is not fully understood. Certainly, many stimuli cause an increase in intracellular calcium concentration and this will activate eNOS (see above). However, covalent modifications to the eNOS protein may also alter its activity or intracellular localization and might provide a mechanism to target eNOS to particulate subcellular fractions or caveolae (specialized invaginations of the plasma membrane that serve as sites for the sequestration of signalling proteins including certain G-proteins, ion channels, protein kinases and receptors). Covalent modifications by which the enzyme is attached to a fatty acid or some other moiety of eN OS have all been described l 2 (acylation, N-terminal myristoylation, reversible palmitoylation and phosphorylation).
The functional significance of these modifications is not yet clear, but bradykinin (an endothelium-dependent dilator) promotes de-palrnitovlation of eNOS and increases in shear stress promote myristoylation. The implications of these findings are that, even if the amount of enzyme stays constant and the level of stimulant stays constant, the amount of NO generation may fall or increase, or it might be localized to one particular area of the endothelial cell. NO generation within the endothelium might also be altered by changes in the amount of eNOS enzyme expressed, and studies in animals suggest that oestrogens can act in this way to cause vascular changes. This effect may contribute to the h I . hanoes i 13 acmoc ynamlc c anges m pregnancy .
Platelets and white cells
NO generated by eNOS is not only released abluminally to relax vascular smooth muscle but also acts on the luminal side where it inhibits platelet aggregation 14 and helps prevent the adhesion of platelets and white cells to the vessel wall. Inhibition of NO generation does not appear to increase the adhesion of platelets to normal vessels, but enhances adhesion to damaged vessels. NO is also generated by activated platelets themselves, and activated platelets release mediators that stimulate eNOS activity in the endothelium. Together, endothelial and platelet generation of NO seems to provide a negative feedback mechanism to limit the extent of intravascular platelet activation. The antiplatelet effects of NO seem to be mediated by effects on cell surface adhesion molecules; NO inhibits the expression of P-sclcctin and I or the .fibrinogen receptor (the lIbI IlIa receptor). The potential importance of the antiplatclct effects of NO is illustrated by studies of experimental vessel stenosis; in the presence of stenosis, vasoactive factors released by the adhering platelets appear to contribute to the generation of cyclical variations in flow. These effects are greatly enhanced if NO generation is blocked.
Atherogenesis
It seems that decreased activity of eNOS would be associated with increased vascular tone, enhanced vascular reactivity to constrictor agents and a predisposition to platelet and white cell adhesion and activation. Diminished endotheliumdependent relaxation has been described in vessels of laboratory animals or patients with overt atherosclerosis or various risk factors including hypercholesterolaemia15, hypertension16 and diabetes17. The possible consequences of diminis~ed NO-mediated effects are becoming clearer. In particular, there is accumulating evidence that a diminution of NO generation, or increased destruction of NO, could promote atherogenesis and provide a mechanism to link apparently disparate risk factors to the single cardiovascular endpoint of atheroma formation. Indeed experiments in cholesterol-fed rabbits have demonstrated that inhibition of NO synthesis promotes the development of atheroma-like lesions, whereas supplementation with L-arginine prevents it 18. The mechanisms might include effects on vascular reactivity and platelet function but also appear to involve infiltration of monocytes. Indeed the expression of monocyte chemotractant protein 1 (MCP-l) on endothelial cells is enhanced by cholesterol loading and is further enhanced if an inhibitor of NOS is administered.
How does NO act to inhibit cellular adhesion and prevent atherogenesis? One suggestion is that part of the protective effect of NO relates to its ability to affect generation or survival of other free radicals, in particular supcroxide (0 2 -) 19, a radical that is produced in excess amounts during cholesterol loading. Activation of the nuclear transcription factor NFKB (a factor that promotes the transcription of a variety of mRNA encoding for inflammatory proteins) is redox sensitive. NFKB is normally bound in an inactive form together with inhibitory factor (IKBex). It is proposed that basal NO prevents generation of O 2 -or interacts with O 2 -to prevent dissociation of the IKBex/NFKB complex and subsequent activation of NFKB. Activation of NFKB initiates transcription of the genes encoding for MCP-l and certain cell surface adhesion molecules including vascular cell adhesion molecule-I (VCAM-l), and the net effect is to promote cellular adhesion and migration. Thus basal NO is seen as providing a continuous brake on the activation of chemoattractants and adhesion molecules through its interaction, either directly or indirectly, with the IKBex/NFKB complex.
Shear stress increases NO generation from eN OS and also makes cells resistant to the activation of NFKB by certain pro-inflammatory cytokines. This raises the intriguing possibility that the predilection of atheroma for sites of low shear stress in the arterial tree may be related to loss of the NO-mediated inhibition of NFKB activation. Activation of NFKB is also involved in iN OS induction (see below), and perhaps the constitutive production of NO by eNOS helps prevent the induction of the inflammatory isoform.
L-arginine supplementation
Supplementation with L-arginine seems to retard the development of atherosclerosis in the cholesterol-fed rabbit, and restores the responses to endothelium-dependent dilator agents in animals and patients with hvpercholesterolaemia. Although L-arginine is the substrate for NOS, the mechanism of this effect is far from clear. The amount of arginine required by the enzyme is in the order of 1 IlmollL and the circulating concentration is in the order of lOOllmollL (i.e. the supply of arginine should not be rate-limiting for NO generation). How arginine exerts its effects remains to be determined. It is curious that arginine supplementation works when given in vivo but usually not when added to vessels from hypercholesterolaemic animals in vitro. One possibility is that the presence of an endogenous inhibitor of NOS (such as asymmetric dimethylarginine; ADMA20) competes with arginine for the active site. Studies arc now underway to explore this and other possibilities.
nNOS in the vasculature
The role of nNOS in cardiovascular control is less clear cut. Nerves containing nNOS (nitrergic nerves) are found lying in the adventitia of certain vessels and provide a neurogenic vasodilator tone. This is well characterized in the corpus cavcrnosurn-", where activation of nitrergic nerves contributes to the process of penile erection. Nitrergic nerves are also thought to be important in the cerebral vasculature where they may help coordinate vasodilatation to ensure that blood flow increases to metabolically active brain tissue [sec below, section on NO in central nervous system (CNS)]. Recently it has also been suggested that nNOS activity may regulate blood pressure (CNS section).
iNOS in the vasculature
In contrast to eNOS and nNOS, iNOS is not normally expressed in healthy vessels, but the enzyme is synthesized de novo in endothelial cells and smooth muscle cells exposed to bacterial endotoxin or certain inflammatory cytokines. Because iNOS activity is calcium-independent, the amounts of NO generated are large, and cause profound vascular relaxation and resistance to constrictor agents. De novo expression of iNOS has been implicated in the pathogenesis of septic hvpotcnsion-", the local vasodilatation associated with chronic inflammation, and the pathogenesis of vascular leak. Experiments in patients confirm that NO is generated in excess quantities in sepsis and that inhibition of NOS with L-NMMA will restore blood pressure n . However, L-NMMA inhibits all three isoforms of NOS and the precise role of iNOS in human inflammatory conditions remains uncertain.
The heart
In addition to its effects on vascular behaviour, NO has been implicated as an endogenous regulator of myocardial contractility and heart rate. NO appears to mediate the negative chronotropic effects of carbachol, at least in neonatal rat myocytes. Moreover, NO seems to be negativeinotropic in many experimental systems and inhibition of NOS may increase contractility of myocytes/" (the situation in vivo is complicated by the increase in afterload due to arteriolar vasoconstriction). The inotrope milrinone has been reported to decrease the expression of eNOS in the heart and this action might contribute to its effect.
iNOS may also contribute to the regulation of myocardial function. In conditions of inflammation, expression of iNOS in the heart leads to excessive suppression of cardiac function. This might explain the acute cardiac dysfunction that accompanies sepsis and also the more chronic changes that occur in certain types of heart failure. In animal models iNOS is expressed during rejection of transplanted hearts and during experimental viral myocarditis, and mRNA for iNOS has been found in all four cardiac chambers of patients with heart failure 25. However, although iNOS expression appears to occur in failing human cardiac myocytes and has been implicated in the pathophysiology of dilated, ischaemic and valvular heart disease, the precise role and effects of iN OS expression remain to be determined. Indeed, it is possible that the NO is produced primarily as a host defence mechanism, and that the cardiac or vascular changes are secondary.
NO IN THE RESPIRATORY SYSTEM
NO may play an important part in regulating airway function and in the pathophysiology of inflammatory airway diseases. Endothelium-derived NO controls airway blood flow and indirectly regulates plasma exudation. Furthermore, just as NO relaxes vascular smooth muscle, so it relaxes the smooth muscle of the airway (albeit less potcntlyj/". NO is a neurotransmitter of bronchodilator nerves in human airways and counteracts the bronchoconstriction due to cholinergic neural mechanisms. Inducible NOS has also been implicated in respiratory pathophysiology; iNOS is expressed in human epithelial cells in response to pro-inflammatory cytokines and oxidants, probably via activation of NFKB.
Expression of iNOS has been found in the epithelium of asthmatic paticnts/" and in macrophages in the lungs of patients with bronchiectasis. The concentration of NO in the exhaled air of patients is increased in inflammatory airways disease, consistent with increased generation of endogenous NO in the lungs. Increased NO production in the airways may' result in hyperaemia, plasma exudation, mucus secretion and (indirectly) increased proliferation of Th2 lymphocytes responsible for eosinophilic inflammation. Glucocorticoids inhibit the induction of iNOS in epithelial cells and reduce the exhaled NO to normal values. Selective inhibitors of iNOS may therefore be useful in the treatment of inflammatory airway diseases, such as asthma (see below).
NO IN THE GASTROINTESTINAL SYSTEM
As in the respiratory system, NO generated by nNOS has been implicated in the control of smooth muscle tone. Indeed the abnormal function of the lower oesophageal sphincter in achalasia is likely to be due to impaired nitrergic inhibitory input 28 and lack of effective nitrergic innervation is associated with pyloric stenosis in animals/? and man 30 . iNOS, too, has been implicated in gut pathology. Gastrointestinal complications commonly arise after administration of non-steroidal anti-inflammatory drugs, and recently the involvement of gut bacterial flora in the generation of non-steroidal-induced inflammation has been explored 31. Indomethacin provoked a time-dependent increase in vascular leakage in the jejunum that was associated with the expression of iNOS activity, suggesting a role of the excessive local generation of NO in the intestinal inflammatory response. This suggestion is supported by the observation that the damage could be limited by giving an NO synthase inhibitor. Interestingly, treatment with the broad-spectrum antibiotic ampicillin was also shown to prevent indomethacin-provoked damage, suggesting a role for local toxins produced by the gut bacterial flora in the processes underlying induction of iNOS following indomethacin.
iNOS seems also to have a central role in the liver, and both parenchymal and non-parenchymal cells synthesize NO alter immune stimulation. Hepatic function is tightly regulated by the interaction of specific cell populations in the liver. Indeed all KupfTer cells, the fixed hepatic macrophages, and hepatocytes express iNOS in response to immune stimulation 32 and the NO generated has both autocrine and paracrine effects. Liver cells can express iNOS in response to a variety of stimuli including Corynebacterium parvum infection, endotoxin and certain cytokines. Within the liver, NO appears to modulate some fundamental intracellular functions such as protein synthesis, mitochondrial electron transport and components of the citric acid cycle.
NO IN THE CENTRAL NERVOUS SYSTEM
The brain possesses the richest capacity to generate NO. A common trigger for NO formation by neurons is activation of receptors for the major excitatory neurotransmitter, glutamate. Of particular significance is the NMDA class of glutamate receptor, whose associated ion channel permits substantial Ca H entry, but other mechanisms causing a rise in cytosolic Ca 2 + in NOS-containing neurons, such as activation of AMPA-type glutamate receptors or metabotropic glutamate receptors (mGluRs) are also likely to be relevant. The main NO synthase isoform in the brain is nNOS although eNOS may be found in certain neurons. Glial cells, and possibly also neurons, can express iNOS after exposure to bacterial lipopolysaccharide and/ or cytokines, at least when the cells are maintained in tissue culture.
In the CNS, NO generated by nNOS is unlike classical neurotransmitters in that it is relatively longlasting and behaves as a diffusible messenger. Because of the high rate of diffusion of NO in both lipid and aqueous environment, a point source is likely to influence neural function over a large tissue volume. A major physiological signal transduction pathway for NO in target structures is stimulation of the soluble form of guanylate cyclase leading to cyclic GMP (cGMP) accumulation.
NO has been implicated in a large number of physiological functions. At the cellular level, these include the acute modulation of neuronal firing behaviour as well as participation in several types of synaptic plasticity (i.e. a cellular basis of memory and learning). nNOS also appears to be important as a regulator of local cerebral blood flow, and behavioural experiments have suggested an involvement of NO in learning, pain, sleep, feeding and sexual function. Pathophysiologically, excessive NO generated by nNOS or iNOS has the capacity to destroy central neurons and is a suspected player in the acute loss of neurons taking place after focal or transient global ischaemia as well as in more chronic degenerative disorders such as Parkinson's disease, multiple sclerosis and motor neuron disease.
Responses to NOS blockade in mutant mice suggest that nNOS may also be involved in maintaining blood pressure. For example, mice lacking the eNOS gene are hypertensive but show a paradoxical fall in blood pressure in response to NOS inhibitors, suggesting that nNOS activity might contribute to increasing pressure. In addition NOS inhibitors cause a fall in cerebral blood flow in both normal mice and in eNOS knockout mice, indicating the possible importance of nN OS in mediating these changes in cerebrovascular reactivity-'.
Early work on the different stroke and cerebral ischaemia models with the NOS-knockout mice has shed some light on the possible role of NO or its reactant products in mediating toxicity in brain 33 • However, controversy continues-partly because of the use of non-selective agents that block NO formation in neuronal, glial, and vascular compartments. For example, in mutant mice deficient in neuronal NOS, infarct volumes at 24 and 72 h after middle cerebral artery occlusion, and the overall neurological deficits, were less than those in normal mice. This result could not be accounted for by differences in blood flow or vascular anatomy. However, infarct size in the mutant became larger after endothelial NOS inhibition by nitro-L-arginine administration. Hence, neuronal NO production appears to exacerbate acute ischaemic injury, whereas vascular NO protects after middle cerebral artery occlusion. These studies demonstrate how disruption of genes by homologous recombination in mice often clarifies the roles of individual genes. However, they also emphasize that many such knockout mice display little or no change in phenotype, suggesting a redundancy of physiological pathways.
THERAPEUTICS
The L-arginine:NO pathway is widespread and involved in a large number of physiological and pathophysiological processes. By analogy with other biological mediators with multiple functions (e.g. serotonin) it might be anticipated that discovery of the pathway will lead to many new therapies. Drugs that donate NO have been in clinical use for well over 100 years: NO is the active constituent of glyceryl trinitrate and is liberated from the parent drug within the body. The existing donors of NO exert their major effect in the cardiovascular system and preferentially dilate veins (possibly because the endothelium of veins docs not generate NO basally and so the smooth muscle is more sensitive to small amounts of NO). The challenge now is to design drugs that differ substantially from existing nitrovasodilators and show specificity for certain tissues, e.g. platelets, nerves, gut, lung. The feasibility of tissueselective targeting of NO is supported by the observation that certain nitrosothiols have potent antiplatelet effects at doses that do not cause significant vasodilatation. There is considerable interest in NO donors that might specifically target the uterus to relax uterine smooth muscle, inhibit uterine contractions and thereby prevent premature labour. A small open label study of glyceryl trinitrate patches in women with premature labour suggests that donation of NO might be beneficial in premature labour, but well-controlled studies are needed.
Inhibitors of NOS might also have therapeutic utility. Indeed the prototype NOS inhibitor L-NMMA is already in clinical trials for the treatment of septic shock, and the results of a multi-centre s:udy are expected in the near future. No doubt selective inhibitors of individual isoforms of NOS are in development and these should allow clearer definition of the roles of each enzyme in disease states. There is considerable interest in the possibility that selective inhibitors of iNOS will have widespread anti-inflammatory effects (sepsis, asthma, gut injury, rheumatoid arthritis). However, although iNOS is readily expressed in rodent cells and tissues, this does not seem to be the case for human beings and the precise role of iNOS in inflammatory conditions and host defence in man remains to be determined.
NO research is now firmly in the clinical arena, and as new drugs are developed and enter clinical trial some putative roles for NO will fall by the wayside and other unexpected effects will be revealed. There is no sign yet that the rate of publications on NO has begun to reach a plateau.
